Lista de obras - Luca Richeldi - Dominio Público Uruguay

"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.

artículo científico publicado en 2018

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective.

artículo científico

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

artículo científico publicado en 2016

Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia

artículo científico publicado en 2015

Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement

artículo científico publicado en 2018

Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis ⬇️

artículo científico publicado el 1 de junio de 2012

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis: The Future of Quantitative Analysis

artículo científico publicado en 2019

Contemporary Concise Review 2018: Interstitial lung disease

artículo científico publicado en 2019

Current Diagnosis and Management of Hypersensitivity Pneumonitis

scientific article published on 10 March 2020

Current and Future Idiopathic Pulmonary Fibrosis Therapy

scientific article published on 11 February 2019

Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies

artículo científico publicado en 2019

Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies

scientific article published on 06 September 2018

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

artículo científico publicado en 2018

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

artículo científico publicado en 2017

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

artículo científico publicado en 2017

Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?

scientific article published on 01 July 2019

Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study

scientific article published on 19 March 2020

Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis

artículo científico publicado en 2017

Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit

scientific article published on 04 March 2019

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial

artículo científico publicado en 2018

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage

artículo científico publicado en 2019

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

artículo científico publicado en 2014

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

scientific article published on 08 January 2020

Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy

artículo científico publicado en 2019

Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis

artículo científico publicado en 2018

Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis

artículo científico publicado en 2014

From pulmonary susceptible tuberculosis to extensively drug resistant tuberculosis: An interesting case report of a young Indian girl

scientific article published on 29 June 2019

How we will diagnose IPF in the future

artículo científico publicado en 2016

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies

artículo científico publicado en 2017

Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers

scientific article published on 01 December 2018

Idiopathic pulmonary fibrosis

artículo científico publicado en 2017

Idiopathic pulmonary fibrosis

artículo científico publicado en 2017

Idiopathic pulmonary fibrosis: CT and risk of death.

artículo científico publicado en 2014

Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history

artículo científico publicado en 2016

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

artículo científico

Idiopathic pulmonary fibrosis: pathogenesis and management.

artículo científico publicado en 2018

Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study

scientific article published on 18 April 2019

Individualizing duration of antibiotic therapy in community-acquired pneumonia

artículo científico publicado en 2017

Interstitial Lung Disease in India. Keep Searching and You'll Keep Finding

artículo científico publicado en 2017

Investigational drugs for idiopathic pulmonary fibrosis.

artículo científico publicado en 2017

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study

artículo científico publicado en 2019

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis

scientific article published on 19 November 2018

Managing patients with interstitial lung disease: Two more pieces of the puzzle.

artículo científico publicado en 2017

Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations

scientific article published on 01 December 2018

Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays.

artículo científico publicado en 2016

Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.

artículo científico publicado en 2018

New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

artículo científico publicado en 2017

Nintedanib for the treatment of idiopathic pulmonary fibrosis.

artículo científico publicado en 2018

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

artículo científico publicado en 2016

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone

scientific article published on 10 January 2019

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report.

artículo científico publicado en 2016

Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study

scientific article published on 11 May 2020

Optimising experimental research in respiratory diseases: an ERS statement.

artículo científico publicado en 2018

Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib

artículo científico publicado en 2019

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

artículo científico publicado en 2018

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence

scientific article published on 21 December 2018

Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study

scientific article published on 07 March 2019

Recent Advances and Future Needs in Interstitial Lung Diseases

artículo científico publicado en 2016

Reply to Moodley and to Ravaglia et al

scientific article published on 01 March 2019

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis

scientific article published on 01 October 2018

Rising to the Challenge of the Novel SARS-coronavirus-2 (SARS-CoV-2): Advice for Pulmonary and Critical Care and an Agenda for Research

artículo científico publicado en 2020

Role of the Quantiferon-TB Test in Ruling Out Pleural Tuberculosis: A Multi-Centre Study ⬇️

artículo científico publicado el 1 de enero de 2011

SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772)

artículo científico publicado en 2018

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.

artículo científico publicado en 2019

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis

artículo científico publicado en 2018

Statin Therapy and Lung Disorders

artículo científico publicado en 2019

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited

artículo científico publicado en 2019

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis

artículo científico publicado en 2019

The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities

scientific article published on 01 May 2019

The characterisation of interstitial lung disease multidisciplinary team meetings: a global study

scientific article published on 01 April 2019

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

artículo científico publicado en 2017

The reply

artículo científico publicado en 2013

The safety of new drug treatments for idiopathic pulmonary fibrosis.

artículo científico publicado en 2016

Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis

scientific article published on 07 August 2018

Treating idiopathic pulmonary fibrosis: current opportunities and future challenges ⬇️

artículo científico publicado el 1 de julio de 2012

Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis

artículo científico publicado en 2020

Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions

artículo científico publicado en 2018

Update in Pulmonary Fibrosis 2018

scientific article published on 01 August 2019

Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis

artículo científico publicado en 2017

Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity

scientific article published on 01 October 2019

X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology

artículo científico publicado en 2019

Lista de obras de Luca Richeldi

"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia

Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement

Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis ⬇️

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis: The Future of Quantitative Analysis

Contemporary Concise Review 2018: Interstitial lung disease

Current Diagnosis and Management of Hypersensitivity Pneumonitis

Current and Future Idiopathic Pulmonary Fibrosis Therapy

Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies

Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?

Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study

Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis

Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy

Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis

Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis

From pulmonary susceptible tuberculosis to extensively drug resistant tuberculosis: An interesting case report of a young Indian girl

How we will diagnose IPF in the future

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies

Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers

Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis: CT and risk of death.

Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

Idiopathic pulmonary fibrosis: pathogenesis and management.

Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study

Individualizing duration of antibiotic therapy in community-acquired pneumonia

Interstitial Lung Disease in India. Keep Searching and You'll Keep Finding

Investigational drugs for idiopathic pulmonary fibrosis.

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis

Managing patients with interstitial lung disease: Two more pieces of the puzzle.

Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations

Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays.

Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.

New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

Nintedanib for the treatment of idiopathic pulmonary fibrosis.

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report.

Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study

Optimising experimental research in respiratory diseases: an ERS statement.

Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence

Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study

Recent Advances and Future Needs in Interstitial Lung Diseases

Reply to Moodley and to Ravaglia et al

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis

Rising to the Challenge of the Novel SARS-coronavirus-2 (SARS-CoV-2): Advice for Pulmonary and Critical Care and an Agenda for Research

Role of the Quantiferon-TB Test in Ruling Out Pleural Tuberculosis: A Multi-Centre Study ⬇️

SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis

Statin Therapy and Lung Disorders

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis

The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities

The characterisation of interstitial lung disease multidisciplinary team meetings: a global study

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

The reply

The safety of new drug treatments for idiopathic pulmonary fibrosis.

Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis

Treating idiopathic pulmonary fibrosis: current opportunities and future challenges ⬇️

Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis

Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions

Update in Pulmonary Fibrosis 2018